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ABSTRACT
Introduction Catheter-related sepsis is one of the most 
dangerous complications of neonatal intensive care and 
is associated with significant morbidity and mortality. Use 
of catheter-care ‘bundles’ has reduced the incidence of 
catheter-related sepsis, although individual components 
have not been well studied. Better evidence is needed 
to guide selection of the most appropriate antiseptic 
solution for skin disinfection in preterm neonates. 
This study will inform the feasibility and design of the 
first randomised controlled trial to examine the safety 
and efficacy of alcohol-based versus aqueous-based 
chlorhexidine antiseptic formulations for skin disinfection 
prior to percutaneous central venous catheterisation in 
preterm neonates. The antiseptics to be compared are 2% 
chlorhexidine gluconate (CHG) aqueous and 2% CHG in 
70% isopropyl alcohol.
Methods and analysis The Antiseptic Randomised 
Controlled Trial for Insertion of Catheters (ARCTIC) is a 
two-centre randomised-controlled feasibility trial. At 
least 100 preterm infants born at <34 weeks’ gestation 
and due to undergo percutaneous insertion of a central 
venous catheter will be randomly allocated to receive prior 
skin disinfection with one of the two antiseptic solutions. 
Outcomes include: i) recruitment and retention rates; ii) 
completeness of data collection; iii) numbers of enrolled 
infants meeting case definitions for definite catheter-
related sepsis, catheter-associated sepsis and catheter 
colonisation and iv) safety outcomes of skin morbidity 
scores recorded daily from catheter insertion until 48 hours 
post removal. The key feasibility metrics will be reported 
as proportions with 95% CIs. Estimated prevalence of 
catheter colonisation will allow calculation of sample size 
for the large-scale trial. The data will inform whether it will 
be feasible to progress to a large-scale trial.
Ethics and dissemination ARCTIC has been approved 
by the National Health Service Health Research Authority 
National Research Ethics Service Committee East of 
England (Cambridge South) (IRAS ID 163868), was 
Strengths and limitations of this study
 ► The Antiseptic Randomised Controlled Trial for 
Insertion of Catheters study will be one of only very 
few randomised controlled trials of skin antisep-
tics in preterm neonates and the first to compare 
aqueous 2% chlorhexidine gluconate versus 70% 
isopropyl alcohol-based 2% chlorhexidine gluconate 
for cutaneous disinfection prior to central venous 
catheterisation.
 ► The trial will collect rigorous, prospective safety data 
following antiseptic application through daily skin 
safety assessments using a validated neonatal skin 
scoring tool.
 ► This will be the first study in neonates to undertake 
molecular typing of isolates to verify that skin-colo-
nising and blood-cultured organisms match cathe-
ter-colonising organisms to a species level in babies 
with suspected sepsis, thus allowing definitive proof 
of catheter-related sepsis.
 ► Catheter colonisation will be used as a proxy for 
catheter sepsis, and the target sample size is based 
on an anticipated incidence of catheter colonisation 
of 20% in the reference antiseptic group, estimated 
with a 95% CI of 11% to 31%; the study is not pow-
ered to detect differences in clinical outcomes.
 ► This trial will show whether a future large-scale 
multicentre randomised controlled non-inferiori-
ty trial of the same antiseptics is feasible and will 
determine the sample size required for such a trial.
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adopted onto the National Institute of Health Research Clinical Research 
Network portfolio (CPMS ID 19899) and is registered with an International 
Standard Randomised Control Trials Number (ISRCTN: 82571474; Pre-
results) and European Clinical Trials Database number 2015-000874-36. 
Dissemination plans include presentations at scientific conferences, 
scientific publications and sharing of the findings with parents via the 
support of Bliss baby charity.
Trial registration number ISRCTN82571474; Pre-results.
InTRoduCTIon
Percutaneously inserted central venous catheters (PCVCs) 
are inserted daily in neonatal intensive care units (NICUs) 
across the world to deliver hyperosmolar parenteral nutri-
tion solutions to preterm neonates. PCVCs may remain 
in situ for weeks,1 but their presence entails a major risk 
for bloodstream infection. In a previous study, 32% of 
inserted PCVCs were colonised with potentially patho-
genic bacteria at the point of removal, and 8% overall 
were associated with definite catheter-related sepsis 
(CRS).1 Extraluminal colonisation is the main route of 
catheter colonisation in short-term CVCs: skin bacteria 
traverse the catheter insertion site onto the catheter, 
colonise the line and act as focus for CRS.2 In one study, 
the presence of skin bacteria at the catheter exit site was 
associated with an 8-fold increased risk of catheter coloni-
sation and a 10-fold increased risk of CRS caused by the 
same organism.2 
For preterm babies in the NICU, CRS is a dangerous 
complication associated with significant morbidity and 
mortality. Sepsis increases the duration of intensive care 
and hospitalisation, need for antibiotics and risks for 
adverse neurodevelopmental outcome. Coagulase-nega-
tive staphylococcal infections cause the majority of CRS in 
the NICU (80%–90%), may be life-threatening and can 
cause permanent lifelong injury and disability in survi-
vors, including cerebral palsy.3 4
Reduction of CRS has been a major goal of the 
National Health Service for the past decade.5 Cathe-
ter-care ‘bundles’, guidelines incorporating collected 
good practices for catheter insertion and maintenance, 
have successfully reduced the incidence of catheter colo-
nisation and CRS in the NICU,6 although await universal 
adoption.7
The individual components of catheter-care bundles 
have not been well studied in randomised controlled 
trials (RCTs). Adequate skin disinfection of the catheter 
insertion site is arguably the most important component 
of catheter-care bundles to prevent catheter colonisation 
and CRS. Optimal skin preparation will abolish or signifi-
cantly reduce numbers of skin organisms, so limiting risks 
of residual skin colonisation by bacteria that may then 
colonise a PCVC and cause CRS.
Studies in adults, including meta-analysis, show that 
alcohol-based antiseptics are superior for topical anti-
sepsis,8 9 and UK national evidence-based guidelines 
recommend use of 2% chlorhexidine gluconate in 70% 
isopropyl alcohol (2%CHG-70%IPA) for skin antisepsis 
in adults and older children. However, there is no 
guidance for preferred antiseptic in infants, including 
preterm infants, due to the lack of evidence and specific 
safety concerns in this population.10 11 The best antiseptic 
to use for preterm babies is still unknown, and multiple 
different antiseptics, combinations and concentrations 
are presently being used in UK NICUs; approximately 
half use a 2% concentration of CHG and 60% an IPA-con-
taining CHG formulation.12 For preterm neonates, there 
is no Cochrane review comparing skin antiseptics for 
cutaneous disinfection prior to PCVC insertion, and only 
two RCTs have compared topical antiseptics for PCVC 
insertion.13 14
There are risks associated with antiseptic use peculiar 
to preterm infants. Their thin skin is vulnerable to chem-
ical injury and absorption. Chemical skin burns have 
been described with all the currently used topical anti-
septics, including both aqueous and alcohol-containing 
CHG formulations, and iodine solutions,15 as well as with 
octenidine.16 Topical alcohol use may also increase the 
risk of systemic chemical absorption.17
There are no published RCTs that have examined the 
safety and efficacy of alcohol-based versus aqueous CHG 
formulations for neonatal antisepsis. This feasibility 
study aims to inform the safety and assist the design and 
planning of a future large-scale multicentre RCT that 
will examine whether 2% CHG aqueous is non-inferior 
in antiseptic efficacy compared with 2%CHG-70%IPA 
for skin disinfection prior to PCVC insertion in preterm 
neonates. An aqueous CHG is likely to have fewer side 
effects than an alcohol-based CHG, and would there-
fore be preferable if found to be non-inferior in terms of 
antisepsis.
oBjECTIvES
To determine the proportion of babies in the 
2%CHG-70%IPA group with colonisation of at least one 
of the two catheter segments taken at catheter removal. 
Catheter colonisation will be the primary outcome in 
the full-scale trial because it is a valid surrogate for CRS2; 
to determine factors affecting recruitment and process 
outcomes that will help refine the design of the large-
scale trial; also to estimate numbers of enrolled infants 
who have definite CRS and numbers with catheter-asso-
ciated sepsis, determine suitability and completeness of 
data collection methods and describe any skin morbidity 
occurring in trial participants related to use of the study 
antiseptics.
METhodS And AnAlySIS
Study design
A feasibility, masked RCT of Investigational Medicinal 
Products (IMPs). Preterm infants born at <34 weeks’ 
gestation who are due to undergo planned inser-
tion of a PCVC will be randomised to receive one of 
two topical disinfection agents for skin antisepsis: 2% 
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chlorhexidine gluconate aqueous (2%CHG-aqueous) or 
2%CHG-70%IPA.
Study setting
Two tertiary-level neonatal units in the UK, Norfolk 
and Norwich University Hospital and Medway Maritime 
Hospital, which each cater to a total of 5000–6000 deliv-
eries per year.
ElIgIBIlITy
Inclusion criteria
 ► Preterm infants born at <34 weeks’ gestation.
 ► Requiring routine insertion of a PCVC for parenteral 
nutrition.
 ► No new episode of suspected sepsis with commence-
ment of antibiotics occurring within the 48 hours 
preceding planned catheter insertion.
 ► No other indwelling PCVC already in situ.
Exclusion criteria
 ► No realistic prospect of survival in the short term.
 ► Life-threatening congenital abnormality.
 ► Underlying skin condition.
 ► Another indwelling PCVC already in situ or previously 
enrolled into the study.
 ► Positive blood culture (BC) within the past 7 days 
without a subsequent negative BC result.
 ► Antibiotic treatment commenced for suspected sepsis 
within the preceding 48 hours.
Key definitions
Definite CRS: a peripheral BC plus any catheter segment 
(ie, one of the ~1 cm long proximal or tip catheter 
portions) positive with the same organism, based on 
bacterial culture, antibiotic sensitivity and molecular 
typing, from a neonate who had an indwelling PCVC and 
clinical signs of sepsis but no other focus of sepsis.
Catheter colonisation: a catheter that at the time of 
removal has either one or both segments that are culture 
positive.
Catheter-associated sepsis: a baby with clinical signs of 
sepsis and an accompanying positive BC in the period 
between catheter insertion and 48 hours post removal but 
who has no other focus of sepsis and in whom both cath-
eter segment cultures are negative.
Recruitment
Preterm babies potentially suitable for the trial will 
be identified by the clinical healthcare teams. Parents 
of such infants will be approached for consent by the 
research team or delegated suitably qualified member of 
the clinical healthcare team trained in study procedures 
and Good Clinical Practice (GCP). A written parent infor-
mation sheet that forms part of the Parental Informed 
Consent Form will be provided to help explain the study 
(online supplementary file 1). Written maternal consent 
will be obtained and countersigned by the person who 
obtained informed consent (principal investigator (PI), 
or appropriately qualified healthcare professional with 
delegated authority).
Randomisation
Following consent, randomisation to either 
2%CHG-70%IPA antiseptic or 2%CHG-aqeuous anti-
septic will take place as close as possible to the time 
of planned catheter insertion. Randomisation will be 
managed via a secure web-based facility hosted by the 
National Perinatal Epidemiology Unit Clinical Trials 
Unit (CTU) and will use a 3:1 allocation ratio in favour 
of the 2%CHG-70%IPA antiseptic group, the group that 
will inform the power calculation for the large-scale trial. 
Groups will be stratified by birth gestation (<28 weeks; 28 
weeks+0 days to 33 weeks+6 days) and by centre. Treat-
ment allocation will be masked such that the allocation 
will not be known by clinicians, the baby’s family, labora-
tory staff or trial outcome assessors.
Interventions
The trial procedures are summarised in figure 1.
Skin disinfection at catheter insertion
Study packs stored in a locked, secure, temperature-mon-
itored cupboard will contain two bottles of the same allo-
cated antiseptic Investigational Medicinal Product (IMP) 
each labelled with the same identifying code. One bottle will 
be opened at catheter insertion, the other will be retained 
for use at catheter removal. The disinfection procedure 
requires sparing application of allocated antiseptic solution 
for 10–20 s from sterile gauze to the skin site area selected 
for catheterisation. Instructions are: use only the minimal 
volume of antiseptic necessary for skin coverage, avoid 
any pooling of antiseptic, ensure that any excess solution 
and any soaked drapes or gowns are removed to avoid any 
prolonged contact with the skin and allow the disinfected 
area to air dry completely (for ≥30 s) before proceeding 
with catheter insertion. Excepting in the case of failed cath-
eterisation, saline or water must not be used to wipe the 
disinfected skin area following application of antiseptic 
solution.
Catheter insertion
Catheter insertion will be standardised, using a working 
guideline common to both participating centres that 
requires strict aseptic technique and encompasses estab-
lished good clinical practices for PCVC insertion and care 
adopted from catheter-care bundles6 8 18 19 The decision to 
insert a PCVC and choice of catheter (Premicath 1Fr/28G 
or Epicutaneo-Cava catheter 2Fr/24G: both Vygon (UK), 
Cirencester, UK) is at the discretion of the attending clin-
ical team. All personnel involved will be trained in catheter 
insertion and maintenance procedures. An insertion check-
list will be completed for all catheterisations and a dispos-
able face mask will be worn by the operator inserting the 
catheter for asepsis purposes and also to minimise the risk of 
possible unblinding from any smell of alcohol.
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Assessment of skin condition
Skin status will be recorded using a validated neonatal 
contact dermatitis scoring system, the Neonatal Skin 
Condition Score,20 with minor modification. Assessments 
will be undertaken by a nurse trained in use of the scoring 
system and will be recorded at baseline (prior to appli-
cation of antiseptic), within 10–30 min after catheter 
insertion and then daily until 48 hours following cath-
eter removal, or daily for 48 hours after antiseptic appli-
cation in cases where catheterisation is unsuccessful. 
Serious chemical skin burns adjudged by a PI or delegate 
to be severe or moderately severe, will be notified to the 
Medicines and Healthcare Products Regulatory Agency 
(MHRA).21
Figure 1 Trial procedures. 
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Catheter removal and obtainment of study specimens
Catheters are usually removed when no longer required, 
although sometimes removal is warranted earlier than 
intended because of complications, including suspected 
sepsis. If a catheter is being removed from a baby with 
suspected sepsis then a concurrent peripheral BC will be 
obtained as per routine clinical practice. The decision for 
catheter removal for enrolled babies lies with the atten-
dant clinical team.
The following samples will be obtained at the time of 
catheter removal for microbiological analysis:
i. Two exit site skin swabs taken before catheter remov-
al: the first after removing all covering dressings but 
prior to skin disinfection; the second taken post new 
disinfection of the insertion site, once the antiseptic 
has dried. This disinfection procedure is intended to 
limit the risk of catheter contamination by residual 
skin organisms during the removal of the catheter 
and will use the same allocated antiseptic as was used 
for catheter insertion. Both specimens will be ob-
tained by rolling the swab tip several times across the 
skin of the catheter insertion site, over an area within 
<0.5 cm radius of the insertion site and including the 
actual puncture site.
ii. Two approximately 1 cm long catheter segments 
(proximal and tip) after catheter removal. Proximal 
catheter segments have higher colonisation rates 
than tips,1 therefore microbiological analysis of both 
catheter segments rather than the tip alone may im-
prove the diagnostic yield of catheter colonisation.
Catheter removal requires two trained persons and care 
to avoid cross-contamination between segments while 
sectioning the catheter. Two separate sets of sterile forceps, 
two pairs of sterile scissors and two sterile prelabelled 
universal containers are required. Before removing the 
catheter, the subcutaneous insertion length will be noted 
from the external catheter markings. The catheter will be 
removed onto a sterile paper towel field then sectioned 
using separate pairs of sterile scissors to obtain two ~1 cm 
long formerly subcutaneous catheter segments: i) tip and ii) 
a proximal segment, taken approximately 1–2 cm distal to 
the point of skin entry (figure 2). The individual segments 
will be placed into separate appropriately labelled sterile 
universal containers using separate pairs of sterile forceps.
Microbiology
The catheter segments and skin swabs will be submitted 
to the local microbiology laboratories for routine culture 
and antibiotic sensitivities. BCs sent from babies with 
suspected sepsis at the time of catheter removal will 
undergo standard culture methods. Bacterial growths 
from skin swab cultures will be assessed using a semi-quan-
titative method.22 All laboratory staff will be blinded 
to antiseptic allocation. Isolates from culture-positive 
skin swabs, blood and catheter segmental cultures will 
be retained for molecular typing. Initial identification 
of organisms will be done by mass spectrometry. Those 
giving similar patterns will be analysed using next-gener-
ation sequencing using a multiplexed approach on the 
Illumina MiSeq. Molecular typing of paired blood and 
catheter isolates from the same baby will allow confirma-
tion that isolates are identical to a species level, for defin-
itive diagnosis of definite CRS. While few postdisinfection 
skin swabs are expected to be positive, molecular typing 
of skin swab isolates will be done for any babies with 
colonised catheters: isolation of paired identical species 
could indicate possible catheter contamination by skin 
organisms during catheter removal. Babies with positive 
BCs will be managed according to local clinical guide-
lines; involvement in this trial will not dictate or influence 
clinical antibiotic prescriptions.
outcome measures
I. Proportion of babies in the 2%CHG-70%IPA arm 
with catheter colonisation as determined by posi-
tive bacterial culture from one or both of the cath-
eter segments taken at catheter removal (primary 
outcome).
II. Rates of recruitment and retention to the study, and 
the collection of views of parents and clinicians on 
factors affecting recruitment and retention.
III. Proportion of infants with positive exit-site skin swabs 
at catheter removal.
IV. Number and type of catheter segments culture posi-
tive at removal.
V. Bacterial species (typed via molecular methods) of 
isolates identified on positive BC, exit-site skin swabs 
and catheter segments.
VI. Proportion of infants undergoing an infection 
screen in the period between catheter insertion and 
48 hours post catheter removal that meets case defi-
nition for definite CRS.
VII. Proportion of infants with positive blood culture 
from any infection screen in the period between 
catheter insertion and 48 hours post catheter remov-
al that meets definition for catheter-associated sepsis.
VIII. Rate of CRS per 1000 PCVC days.
IX. Rate of catheter-associated sepsis per 1000 PCVC 
days.
Figure 2 Picture showing catheter sections taken at 
catheter removal.
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X. Proportion of infants completing the study with 
complete data for the primary outcome and propor-
tions of infants with missing data collection forms.
XI. Daily skin morbidity scores in the period between 
catheter insertion and 48 hours post catheter remov-
al, and in the period between antiseptic application 
and 48 hours post antiseptic application where cath-
eterisation was unsuccessful.
Supportive care of participants
The clinical management of babies enrolled in the study 
will follow standard local practices. For the purposes of 
this feasibility study, if CRS is suspected the ideal will be 
catheter removal at that time. However, it is recognised 
that a pragmatic approach is sometimes needed, especially 
for very premature babies in whom catheter replacement 
may be difficult and challenging. Efforts will be made to 
minimise local differences in treatment practices between 
sites through training.
discontinuation of trial intervention
The trial intervention will be stopped on parental request, 
or if the baby develops serious adverse skin damage that, in 
the opinion of the responsible PI, was caused by the IMP. 
Thus, if any baby has a clinically significant chemical skin 
burn following IMP application at catheter insertion then 
the allocated antiseptic will be withheld from use for skin 
disinfection at catheter removal. In such instance, skin swab 
and catheter sections will still be obtained as per removal 
procedure and the protocol deviation will be recorded.
Blinding and unblinding
The antiseptic IMPs will be manufactured by a MHRA-ac-
credited Specialist Pharmacy Manufacturing Unit 
compliant with Good Manufacturing Practices. The IMP 
will be supplied in bottles and both products will be 
coloured pink (using carmoisine) and visually indistin-
guishable. To maintain blinding, each baby will be issued 
a unique allocation number corresponding to the study 
pack number. Emergency unblinding for valid medical 
or safety reasons is via the randomisation website using 
a single-use access code provided in a sealed envelope in 
the Investigator Site File.
Sample size
Our previous study found that 32% of PCVCs had a 
colonised tip and/or proximal segment at removal after 
using much weaker concentration (0.015%–0.05%) CHG 
solutions and the definite CRS rate was 6.8 per 1000 cath-
eter days.1 In comparison, a UK NICU that routinely used 
2%CHG-70%IPA for PCVC insertions reported a 34% 
lower CRS rate (4.5 per 1000 catheter days).18 Presuming 
that alcohol-based 2%CHG is the major factor of benefit 
in catheter care, by extrapolation we might reasonably 
expect to see a 34% reduction in extraluminal catheter 
colonisation rates by using 2%CHG-70%IPA solution. 
Thus, we estimate a catheter colonisation rate of approx-
imately 20% (0.66×32%=21%) may be achieved with 
2%CHG-70%IPA solution. A 3:1 allocation ratio in favour 
of the reference 2%CHG-70%IPA group requires a target 
sample size of approximately 93 babies with successfully 
inserted (and removed) catheters (ie, n=70 in the refer-
ence group) to estimate the critical parameters for a 
future, large-scale trial with an adequate degree of preci-
sion. With this target sample size, the anticipated inci-
dence of the primary outcome in the reference group of 
20% will be estimated with a 95% CI of 11% to 31%. With 
a sample size of 93 babies with successfully inserted cath-
eters, the anticipated recruitment/uptake rate of 75%13 
will be estimated with a 95% CI of 0.65 to 0.83. A sample 
size of approximately 93 babies having catheters success-
fully inserted/removed will require parents of at least 124 
eligible babies to be approached.
data management and analysis
Outcome data include routinely recorded clinical infor-
mation obtainable from clinical and local microbiolog-
ical laboratory records. Data verifying species of catheter 
colonisation will be collected following further analysis of 
positive isolates by molecular typing. Data will be collected 
using study-specific data collection forms for: trial entry 
and randomisation, main outcome data (catheter inser-
tion, skin condition assessment, sepsis evaluation and 
antimicrobial therapy), catheter removal, microbiology 
data, unsuccessful catheterisation episodes, discontinua-
tion of intervention, withdrawal and foreseeable serious 
adverse events (SAEs). In addition, information will be 
collected and reported to the sponsor using the sponsor’s 
SAE report form and incident form, to report any devia-
tion from the protocol, trial-specific procedures or GCP.
Data collection will proceed from randomisation until 
48 hours post catheterisation for successfully inserted 
catheters, or until 48 hours after last antiseptic application 
for unsuccessful catheterisation. If a baby is discharged 
from its recruiting centre before study completion, to try 
to achieve complete follow-up safety data, the research 
team will contact the receiving clinical nursing team to 
request routine daily documentation regarding status of 
catheter insertion site skin and details of any new clinical 
sepsis events until 48 hours post catheter removal.
All data will be collected, transferred and stored in 
compliance with GCP and current data protection legis-
lation. The trial co-ordinating centre (Norwich) will 
hold the main administrative database for the trial. Data 
acquired by the enrolling units will initially be recorded 
onto paper data collection forms, followed by entry into 
an OpenClinica database (OpenClinica, Waltham, USA) 
administered by the National Perinatal Epidemiology 
Unit. Access to this database will be via a web browser 
and restricted to authorised users. The database has 
been tested and validated prior to use. All data collec-
tion, transfer and storage will comply with GCP and Data 
Protection legislation.
Statistical analysis plan
A statistical analysis plan for proposed analysis and 
presentation of the results of the trial will be drawn up 
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by the delegated CTU medical statistician. Drafts will be 
reviewed by CTU personnel, by the CI and by the chair of 
the Trial Steering Committee (TSC) and a final version 
will be approved prior to the end of recruitment. Any 
deviations from the plan will be described and justified in 
the final report. Analysis will be carried out by an appro-
priately qualified and experienced statistician, who will 
ensure the integrity of the data during their processing.
Site training
Each recruiting centre is staffed by a local research nurse 
dedicated to support the study. Initiation visits at each partic-
ipating neonatal unit will be performed by the CI and study 
research nurse, also attended by the sponsor’s representa-
tive. Training in study-specific procedures and in awareness 
of the principles of GCP will be provided for nursing and 
medical staff in each site by the local PI and research nurses, 
who will also help maintain training and delegation logs.
Monitoring
The sponsor’s nominated representatives will undertake 
monitoring visits during the course of the study at each 
recruiting site to check for completeness and quality of 
data collection and adherence to the study protocol and 
reporting requirements. A monitoring plan is in place to 
determine the frequency and scope of site monitoring 
based on continuing risk review. Face-to-face monitoring 
visits will initially be undertaken within the first 6 months 
and the frequency and mode of ongoing site monitoring 
will be revised following assessment of recruitment rates, 
number of data queries and safety/incident reports.
Pharmacovigilance
Safety of participants will be assessed continuously from 
randomisation until 48 hours post catheter removal. 
The frequency of adverse events and SAEs as defined by 
The International Council for Harmonisation and that 
would normally require reporting within a clinical trial is 
expected to be high in this population. In accordance with 
regulatory guidance which allows for exceptions in such 
circumstances, a modified reporting plan was approved 
by the research ethics committee and by the MHRA. This 
plan exempted the need for routine reporting of prespec-
ified SAEs that are a foreseeable occurrence in preterm 
babies, unless considered causally related to IMP or trial 
procedures. Unforeseeable SAEs will be reported on the 
sponsor’s SAE form. The relationship of each adverse 
event to the trial medication will be determined by a 
medically qualified individual. All reportable SAEs with 
causality assessed as ‘possibly’, ‘probably’ or ‘definitely’ 
will be considered as related to IMP. All SAEs assigned 
by the PI or delegate (or following sponsor/CI review) 
as suspected to be related to IMP and unexpected will be 
classified as suspected unexpected serious adverse reac-
tions and subject to expedited reporting to the MHRA.
data and safety monitoring
The Data Monitoring Committee (DMC) is responsible 
for safeguarding the interests of the trial participants and 
making recommendations to the TSC. The ARCTIC DMC 
roles, responsibilities and operating procedures are defined 
in the ARCTIC DMC Charter. The DMC is composed of 
three independent multidisciplinary experts who are not 
involved in the conduct of the trial in any way. They met 
prior to the initiation of enrolment and determined a plan 
to review the protocol, compliance, safety and outcome data 
after 50 babies had been recruited. The TSC is composed 
of eight independent members and has a Charter defining 
members’ roles and responsibilities. Its Chair and the 
majority of the TSC membership are independent of the 
trial. The TSC provides the overall supervision, monitors 
progress and conduct of the trial and advises on its scientific 
credibility. The TSC will consider and act, as appropriate, 
on any recommendations of the DMC and carries ultimate 
responsibility for deciding whether the trial needs to be 
stopped on grounds of safety or efficacy. The TSC will report 
on trial progress to the trial funder.
Patient and public involvement
The study proposal benefited from extensive patient and 
public involvement during its development. Advice received 
included regarding content of the Parental Informed 
Consent Form and aspects of protocol design. Input was 
received from Bliss baby charity ( www. bliss. org. uk), by 
PPIRes (http:// nspccro. nihr. ac. uk/ public- and- patient- 
involvement- in- research) and by a consumer member repre-
sentative of the Neonatal Clinical Specialty Group of the 
Medicines for Children Research Network. We also consulted 
with a local parent support group and with parents of babies 
who had suffered CRS. Two lay members are involved in trial 
management as members of the TSC, and will be involved in 
dissemination of findings.
Ethics and dissemination
Clinical trial authorisation was granted by the MHRA (REF: 
13630/0009/001–0001). Written approvals were received 
from individual hospital sites prior to recruitment. The trial 
commenced recruitment under protocol V.3.0, dated 18 
November 2016; the full protocol is available at: https://
www. npeu. ox. ac. uk/ arctic. The investigator or a suitably 
qualified person designated by the local PI will obtain written 
informed consent from the patient’s parent/legally accepted 
representative before any trial-specific activity is performed. 
The CI will ensure that the trial is conducted in accordance 
with the principles of the Declaration of Helsinki and in 
conformity with GCP. The trial’s findings will be presented 
at national and international scientific meetings and confer-
ences and will be published in an open access peer-reviewed 
journal.
ConCluSIonS
Recruitment to ARCTIC commenced in March 2017 and the 
projected overall trial end date is 31 March 2019. It is hoped 
that the findings of this feasibility study will pave the way for 
the definitive large-scale efficacy/safety study. The antici-
pated large-scale study will be a multicentre non-inferiority 
RCT of the same two antiseptics for skin disinfection prior to 
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PCVC insertion in preterm neonates. Primary outcome will 
be catheter colonisation as determined by culture of one or 
more catheter segments taken at catheter removal. National 
evidence-based guidelines for preventing healthcare-associ-
ated infections in the NHS (‘epic’), commissioned by the 
Department of Health, were published in 2001, 2007 and 
2014 to incorporate new research evidence.10 11 Due to the 
lack of previous quality RCTs in the preterm population, no 
previous guidelines included advice or recommendations 
on antiseptics specific for preterm neonates. We anticipate 
that the findings from this research will be incorporated into 
a future version of the epic guidelines.
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